Clinical trials: gemcitabine hydrochloride
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either…
- Trial name
- NCT02409342
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin
- Where
- 142 sites in United States, Brazil and 17 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Metastatic Pancreatic Cancer
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.
- Trial name
- NCT00922896
- Testing
- Gemcitabine, Cisplatin, Erlotinib (Tarceva)
- Where
- 3 sites in South Korea
- Volunteers
- 22 people
- Sponsor
- Gyeongsang National University Hospital
Ovarian Cancer, Fallopian Tube Cancer
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Patients who have this kind of cancer are often treated with several drugs. Carboplatin is one that seems to work for many treatment cycles. Even though it may work against the cancer, the patient can become allergic to it.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01248962
- Testing
- carboplatin
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Chemotherapy and G-CSF for Mobilization
This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in…
- Trial name
- MOCCCA (NCT03442673)
- Testing
- Vinorelbine, Gemcitabine, G-CSF
- Where
- Switzerland
- Volunteers
- 137 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Durvalumab, Intrahepatic Cholangiocarcinoma
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC
- Conditions
- Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis
- Trial name
- NCT05672537
- Testing
- Durvalumab, Surgery, Gemcitabine
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nasopharyngeal Carcinoma, EBV Related Carcinoma
Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours
The aim of the present investigation is to test of the modulation obtained with denosumab as "priming" therapy before the start of chemotherapy and as concurrent therapy in a population of first line NPC recurrent/metastatic…
- Trial name
- Dern (NCT03923842)
- Testing
- Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care
- Where
- 2 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Pancreas Cancer
Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
To determine recommended phase 2 dose and to evaluate the safety of vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed first-line gemcitabine and…
- Trial name
- NCT04258072
- Testing
- Vactosertib
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Samsung Medical Center
Non-small Cell Lung Cancer
Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the 1-year treatment failure rate of two sequential chemotherapy regimens: weekly docetaxel plus cisplatin followed by gemcitabine; and gemcitabine plus cisplatin followed by weekly…
- Trial name
- NCT00173888
- Testing
- Docetaxel, Cisplatin, Gemcitabine, Cisplatin
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- National Taiwan University Hospital
Solid Tumors
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I study with escalating doses of PM060184 in combination with gemcitabine in selected patients with advanced solid tumors.
- Trial name
- NCT02533674
- Testing
- Gemcitabine plus PM060184
- Where
- 2 sites in United States, Spain
- Volunteers
- 57 people
- Sponsor
- PharmaMar
Advanced Pancreatic Cancer
Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer
The main research objective is to work out the optimal doses of the novel combination of gemcitabine, oxaliplatin and imatinib mesylate (glivec) in patients with advanced pancreatic cancer that has progressed during or after…
- Trial name
- RPGOG1 (NCT01048320)
- Testing
- Gemcitabine, Oxaliplatin, Imatinib
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreatic Neoplasms Malignant, Malignant Neoplasm of Gall Bladder Non-resectable
Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers
SUMMARY PROJECT TITLE: Concurrent chemo-radiation using Tomotherapy based IMRT in locally advanced Gallbladder and Pancreatic cancers: A Phase II study SPECIFIC OBJECTIVES: Primary To assess the radiological response by dose…
- Trial name
- NCT01118897
- Testing
- Tomotherapy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Hospital
Biliary Tract Cancer
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
FOLFIRI as a salvage treatment in metastatic biliary tract cancer (BTC) patients who failed gemcitabine containing chemotherapy
- Trial name
- NCT03110510
- Testing
- Fluorouracil, Irinotecan Hydrochloride, leucovorin calcium
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Carcinoma, Non-Small-Cell Lung
A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer
Primary to evaluate the 1-year treatment failure rate of two sequential chemotherapy regimens: 1. weekly docetaxel plus cisplatin followed by gemcitabine and 2. gemcitabine plus cisplatin followed by weekly docetaxel.
- Trial name
- NCT00270582
- Testing
- Taxotere, Cisplatin, Gemcitabine
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Far Eastern Memorial Hospital
Soft Tissue Sarcoma
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
The purpose of this Phase 1 research study is to obtain data or information on the safety and effectiveness of the combination of gemcitabine, docetaxel with radiation.
- Trial name
- NCT04037527
- Testing
- Gemcitabine, Docetaxel, Radiation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Cancer
Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
This study will evaluate the role of Gemcitabine and Abraxane in the treatment of resectable and borderline-resectable pancreatic cancer by giving the chemotherapy before surgery.
- Trial name
- GAIN-1 (NCT01470417)
- Testing
- Chemotherapy, Chemotherapy + ChemoRadiotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02181218
- Testing
- Romidepsin, Gemcitabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
This pilot clinical trial studies gemcitabine hydrochloride, docetaxel, and radiation therapy in treating patients with uterine sarcoma that has been removed by surgery.
- Conditions
- Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma
- Trial name
- NCT01958580
- Testing
- Gemcitabine Hydrochloride, Docetaxel, Internal Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Albert Einstein College of Medicine
Ovarian Cancer
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy
Determination of total survival under Topotecan Monotherapy, Topotecan + Etoposide and Topotecan + Gemcitabine in second-line therapy in patient with recurrent ovarian cancer.
- Trial name
- NCT00312988
- Testing
- Hycamtin, Gemcitabine
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can…
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06632327
- Testing
- Surgical Procedure, Cisplatin, Carboplatin
- Where
- 415 sites in United States
- Volunteers
- 37 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival outcomes, even when treated with modern chemotherapy and radiation.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- PRISM-TAMP (NCT07477418)
- Testing
- Gemcitabine Delivered by Transarterial Microperfusion
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Vermont
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.